Randomized discontinuation design: Application to cytostatic antineoplastic agents

Journal of Clinical Oncology

Volumn 20, Issue 22, 2002, Pages 4478-4484

  Rosner, Gary L ^a   Stadler, Walter ^a   Ratain, Mark J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOSTATIC AGENT; IMIDAZOLE DERIVATIVE;

ARTICLE; CANCER RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOSTASIS; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG SCREENING; EXPERIMENTAL DESIGN; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; KIDNEY NEOPLASMS; RESEARCH DESIGN;

EID: 0037112181     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.11.126     Document Type: Article

References (28)

1. Wittes RE, Marsoni S, Simon R, et al: The phase II trial. Cancer Treatment Reports 69:1235-1239, 1985
2. Simon R: How large should a phase II trial of a new drug be? Cancer Treatment Reports 71:1079-1085, 1987
3. Simon R, Wittes RE, Ellenberg SS: Randomized phase II clinical trials. Cancer Treatment Reports 69:1375-1381, 1985
4. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10. 1989
5. Korn EL, Arbuck SG, Pluda JM, et al: Clinical trial designs for cytostatic agents: Are new approaches needed? J Clin Oncol 19:265-272, 2001
6. Kopec JA, Abrahamowicz M, Esdaile JM: Randomized discontinuation trials: Utility and efficiency. J Clin Epidemiol 46:959-971, 1993
7. Glynn RJ, Buring JE, Hennekens CH: Concerns about run-in periods in randomized trials. JAMA 279:1526; discussion 1527, 1998 (letter)
8. Rini BI, Vogelzang NJ: Prognostic factors in renal carcinoma. Semin Oncol 27:213-220, 2000
9. Gehan EA, Freireich EJ: Non-randomized controls in cancer clinical trials. N Engl J Med 290:198-203, 1974
10. Moertel CG: Improving the efficiency of clinical trials: A medical perspective. Stat Med 3:455-468, 1984
11. Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials (Ed 3). New York, NY, Springer-Verlag New York, Inc, 1998
12. Jones B, Kenward MG: Design and Analysis of Cross-Over Trials. London, United Kingdom, Chapman and Hall, 1989
13. Schwartz D, Lellouch J: Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 20:637-648, 1967
14. Kohn EC, Felder CC, Jacobs W, et al: Structure-function analysis of signal and growth inhibition by carboxyamido-triazole, CAI. Cancer Res 54:935-942, 1994
15. Kohn EC, Reed E, Sarosy G, et al: Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 56:569-573, 1996
16. Kohn EC, Liotta LA: Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 55:1856-1862, 1995
17. Kohn EC, Alessandro R, Spoonster J, et al: Angiogenesis: Role of calcium-mediated signal transduction. Proc Nat Acad Sci USA 92:1307-1311, 1995
18. Teicher BA, Holden SA, Chen YN, et al: CAI: Effects on cytotoxic therapies in vitro and in vivo. Cancer Chemother Pharmacol 34:515-521, 1994
19. Kohn EC, Sandeen MA, Liotta LA: In vivo efficacy of a novel inhibitor of selected signal transduction pathways including calcium, arachidonate, and inositol phosphates. Cancer Res 52:3208-3212, 1992
20. Lambert PA, Somers KD, Kohn EC, et al: Antiproliferative and antiinvasive effects of carboxyamido-triazole on breast cancer cell lines.Surgery 122:372-378, 1997
21. Norton L: A Gompertzian model of human breast cancer growth. Cancer Res 48:7067-7071, 1988
22. Therasse P, Arbuck SG, Eisenhauer EA. et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
23. Armitage P: Statistical Methods in Medical Research. Oxford, United Kingdom, Blackwell Scientific Publications, 1971
24. O'Brien PC, Fleming TR: A multiple testing procedure for clinical trials. Biometrics 35:549-556, 1979
25. Von Hoff DD: There are no bad anticancer agents, only bad clinical trial designs: Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. Clinical Cancer Res 4:1079-1086. 1998
26. Mick R, Crowley JJ, Carroll RJ: Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin Trials 21:343-359, 2000
27. Leber PD, Davis CS: Threats to the validity of clinical trials employing enrichment strategies for sample selection. Control Clin Trials 19:178-187, 1998
28. Summers WK, Majovski LV, Marsh GM, et al: Oral tetrahydroaminoacridine in long-term treatment of senile dementia. N Engl J Med 315:1241-1245, 1986